ArticleFrontiers in pharmacology2022

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.

Jiangping Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.